// App-Quantinova.ai

3080 : Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).

Researchers

Presenter

  • Andreea Varga

Principal Investigators

  • Capucine Baldini

  • Patricia Martin-Romano

  • Benjamin Besse

  • David Planchard

  • Stephane Champiat

  • ERIC ANGEVIN

  • Antoine Hollebecque

  • Rastislav Bahleda

  • Anas Gazzah

  • Jean-Pierre Armand

  • Xavier Paoletti

  • Christophe Massard

  • Jean-Charles Soria

  • Aurelien Marabelle

Medical Centers

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Drug Development Department (DITEP), Gustave Roussy, Villejuif, France

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Gustave Roussy, Villejuif, France

  • Institut Gustave Roussy, Nantes, France

  • Institut Gustave-Roussy, Villejuif, France

  • Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France

  • Institut Claudius Regaud, Toulouse, France

  • Institut Curie, Paris Cedex, France

  • Gustave Roussy Cancer Campus, Villejuif, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Nintedanib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT02856425

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved